Your browser doesn't support javascript.
loading
Patients' Preference Between DPP4i and SGLT2i for Type 2 Diabetes Treatment: A Cross-Sectional Evaluation.
Costa Gil, José Esteban; Garnica Cuéllar, Juan Carlos; Perez Terns, Paula; Ferreira-Hermosillo, Aldo; Cetina Canto, José Antonio; Garduño Perez, Ángel Alfonso; Mendoza Martínez, Pedro; Rista, Lucas; Sosa-Caballero, Alejandro; Vázquez-Mendez, Estefanía; Tejado Gallegos, Luis Fernando; Chen, Hungta; Elizalde, Agustina; Tomatis, Virginia B.
Afiliação
  • Costa Gil JE; Departamento de Endocrinología, Instituto de Cardiología La Plata, La Plata, Buenos Aires, Argentina.
  • Garnica Cuéllar JC; Departamento de Endocrinología del Centro Médico Nacional "20 de Noviembre", ISSSTE, Ciudad de México, México.
  • Perez Terns P; Dirección Médica, Cardiología Palermo - Centro de Investigaciones Clínicas, Buenos Aires, Argentina.
  • Ferreira-Hermosillo A; Unidad de Investigación Médica en Enfermedades Endócrinas. Centro Médico Nacional Siglo XXI, IMSS, Ciudad de México, México.
  • Cetina Canto JA; Hospital Regional ISSSTE, Mérida, Yucatán estado, México.
  • Garduño Perez ÁA; Departamento de Endocrinología del Centro Médico Nacional "20 de Noviembre", ISSSTE, Ciudad de México, México.
  • Mendoza Martínez P; Endocrinología, Hospital Angeles Lindavista, Ciudad de México, México.
  • Rista L; Diabetes, Innovación e Investigación, Centro de Diabetes y Nutrición - Investigaciones Clínicas (CEDyN), Rosario, Santa Fé, Argentina.
  • Sosa-Caballero A; Endocrinología, Hospital Angeles Lindavista, Ciudad de México, México.
  • Vázquez-Mendez E; Medical Affairs, AstraZeneca - México, Ciudad de México, México.
  • Tejado Gallegos LF; Medical Affairs, AstraZeneca - México, Ciudad de México, México.
  • Chen H; Global Medical & Payer Evidence Statistics, AstraZeneca, Gaithersburg, Maryland, USA.
  • Elizalde A; Medical Affairs, AstraZeneca - South Cone, Buenos Aires, Argentina.
  • Tomatis VB; Medical Affairs, AstraZeneca - South Cone, Buenos Aires, Argentina.
Patient Prefer Adherence ; 16: 1201-1211, 2022.
Article em En | MEDLINE | ID: mdl-35592774
ABSTRACT

Purpose:

Despite newer type 2 diabetes (T2D) medications, patients do not always achieve metabolic targets, remaining at risk for cardiorenal complications. Therapeutic decisions are generally made by the healthcare team without considering patients' preferences. We aimed to evaluate patients' T2D treatment preference in two Latin-American countries between two different oral medication profiles, one resembling dipeptidyl peptidase-4 inhibitors (DPP4i) and another resembling sodium-glucose cotransporter-2 inhibitors (SGLT2i). Patients and

Methods:

In this cross-sectional, multicenter study from June to September 2020, patients with T2D from Argentina and Mexico (n = 390) completed a discrete choice experiment questionnaire to identify preferences between DPP4i (medication profile A) and SGLT2i (medication profile B). The reason behind patients' choice, and the association between their baseline characteristics and their preference were evaluated using logistic regression methods.

Results:

Most participants (88.2%) preferred SGLT2i's profile. Participants with older age (p = 0.0346), overweight or obesity (p < 0.0001), high blood pressure (BP; p < 0.0001), high total cholesterol (p = 0.0360), and glycosylated hemoglobin (HbA1c) <7% (p = 0.0001) were more likely to choose SGLT2i compared with DPP4i's profile. The most and least important reasons to choose either drug profile were HbA1c reduction and genital infection risk, respectively. The likelihood of selecting the SGLT2i's profile significantly increased in participants with increased body mass index (BMI; odds ratio [OR] = 8.9, 95% confidence interval [CI] 3.5-22.5, p < 0.05), high BP (OR = 4.9, 95% CI 1.9-12.4, p < 0.05), and lower education level (OR = 3.6, 95% CI 1.0-12.6, p < 0.05).

Conclusion:

Latin-American patients with T2D preferred medication with a profile resembling SGLT2i over one resembling DPP4i as a treatment option. A patient-centered approach may aid the healthcare team in decision-making for improved outcomes.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Prevalence_studies / Prognostic_studies / Risk_factors_studies Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Prevalence_studies / Prognostic_studies / Risk_factors_studies Idioma: En Ano de publicação: 2022 Tipo de documento: Article